Global burden of vaccine-associated kidney injury using an international pharmacovigilance database.

ingentiumby ingentium

In Clinical Literature.

Global burden of vaccine-associated kidney injury using an international pharmacovigilance database.

Publication date: Feb 12, 2025

Global evidence on the association between vaccines and renal adverse events (AEs) is inconclusive. This pharmacovigilance study analyzed a total of 120,715,116 reports from VigiBase collected between 1967 and 2022. We evaluated the global reporting of acute kidney injury (AKI), glomerulonephritis (GN), and tubulointerstitial nephritis (TIN) and assessed disproportionate signals between vaccines and renal AEs using reporting odds ratios (ROR) and the lower limit of the 95% confidence interval of the information component (IC) in comparison with the entire database. The number and proportion of reports on AKI, GN, and TIN gradually increased, with a substantial increase after 2020. Disproportionate reporting of AKI was significant for COVID-19 mRNA vaccines (ROR, 2. 38; IC, 1. 09). Fourteen vaccines were significantly disproportionate for higher GN reporting, and the highest disproportionality for GN reporting was observed for COVID-19 mRNA (ROR, 13. 41; IC, 2. 90) and hepatitis B vaccines (ROR, 11. 35; IC, 3. 18). Disproportionate TIN reporting was significant for COVID-19 mRNA (ROR, 2. 43; IC, 0. 99) and human papillomavirus (ROR, 1. 75; IC, 0. 19) vaccines. Significant disproportionality in the reporting of AKI, GN, and TIN was observed in patients exposed to multiple vaccines, including COVID-19 mRNA vaccines, alongside increasing global reports of vaccine-associated renal AEs.

Open Access PDF

Concepts Keywords
Global Acute Kidney Injury
Inconclusive Acute kidney injury
Kidney COVID-19
Papillomavirus COVID-19 Vaccines
Pharmacovigilance COVID-19 Vaccines
Databases, Factual
Female
Glomerulonephritis
Glomerulonephritis
Humans
Male
Nephritis, Interstitial
Pharmacovigilance
Pharmacovigilance
SARS-CoV-2
Tubulointerstitial nephritis
Vaccines

Semantics

Type Source Name
disease MESH acute kidney injury
disease MESH glomerulonephritis
disease MESH tubulointerstitial nephritis
disease MESH COVID-19
disease MESH hepatitis
disease MESH Hypertension
drug DRUGBANK Coenzyme M
disease IDO immune response
pathway REACTOME Immune System
disease MESH myocarditis
disease MESH arthritis
disease MESH encephalomyelitis
disease MESH autoimmune disease
disease MESH Uncertainty
disease MESH adverse drug reactions
disease IDO quality
disease MESH diphtheria
disease MESH tetanus
disease MESH pertussis
pathway KEGG Pertussis
disease MESH polio
disease MESH influenza
disease MESH measles
pathway KEGG Measles
disease MESH mumps
disease MESH rubella
disease MESH varicella
disease MESH zoster
disease MESH tuberculosis
pathway KEGG Tuberculosis
disease MESH typhoid
disease MESH encephalitis
disease MESH anthrax
disease MESH cholera
disease MESH brucellosis
disease MESH plague
disease MESH typhus
disease MESH leptospirosis
disease MESH rabies
disease MESH yellow fever
disease MESH smallpox
disease MESH causality
disease IDO country
disease MESH sequelae
disease MESH Fatal outcomes
disease MESH arrhythmia
disease MESH heart failure
disease MESH cardiac disease
disease MESH Hyperthermia
disease MESH syndrome
disease MESH hypersensitivity
disease MESH relapse
disease IDO susceptibility
disease MESH Asthma
pathway KEGG Asthma
disease MESH autoimmunity
drug DRUGBANK L-Aspartic Acid
drug DRUGBANK Ibrutinib
disease MESH Morbidity
drug DRUGBANK Hexachlorophene
disease IDO blood
drug DRUGBANK Rituximab
disease MESH infections
disease MESH kidney diseases
disease MESH Nephrotic syndrome
disease MESH vasculitis
drug DRUGBANK Aspartame
disease MESH IgA vasculitis
pathway REACTOME Reproduction

Original Article

(Visited 3 times, 1 visits today)